# Lantern Laboratory Inc.

> Lantern Laboratory is a New York medical-device startup developing an intraoperative brain monitor that analyzes EEG signals in real time to help anesthesia teams distinguish sedation from pain response and account for a patient's cognitive age. Built on Columbia University research and data from more than 2,000 surgeries, the platform is aimed at hospitals, operating rooms and intensive-care settings where better drug titration could support smoother emergence and fewer postoperative cognitive complications.

- **Founded:** 2022
- **Headquarters:** New York City, United States
- **Founders:** Meera Garcia, MD, FACOG (Co-founder and CEO), Paul S. Garcia, MD, PhD (Co-founder and scientific inventor)
- **Team size:** Approximately 3 employees; public LinkedIn lists a 2-10 employee range.
- **Products:** Intraoperative brain-monitoring platform, AlphaMax
- **Notable:** Won the 2023 National Institute on Aging Start-Up Challenge and Accelerator and a $60,000 cash award., Selected for Creative Destruction Lab Toronto's 2024/25 Neuro stream., Built its approach around EEG data from more than 2,000 surgeries at Columbia University.

## Products & services

- **Intraoperative brain-monitoring platform** — A device and software platform that analyzes EEG signals in real time to provide patient-specific information on cognitive age, sedation and nociception for pharmacological decision-making in operating rooms and intensive care.
- **AlphaMax** — The name used in a 2025 randomized trial of EEG-guided fentanyl and desflurane titration and in a 2026 Lantern Laboratory trademark application for brain-electrical-activity software as a medical device.

## Achievements

- Won the 2023 National Institute on Aging Start-Up Challenge and Accelerator and a $60,000 cash award.
- Selected for Creative Destruction Lab Toronto's 2024/25 Neuro stream.
- Built its approach around EEG data from more than 2,000 surgeries at Columbia University.
- Secured an exclusive Columbia University license to develop related EEG technology.
- Raised $500,000 from nine investors through a 2023 debt and warrant offering.
- Advanced AlphaMax into a randomized clinical trial published in 2025.

## Latest updates

- **2026-04** — Lantern Laboratory filed a U.S. trademark application for ALPHAMAX covering software as a medical device for diagnosing electrical activity of the brain.
- **2025-09** — The AlphaMax trial part 1 was published; EEG-guided titration had a limited effect on oscillatory alpha power and did not produce an appreciable difference in clinical outcomes.
- **2024-09** — Lantern was selected for Creative Destruction Lab Toronto's 2024/25 Neuro stream.
- **2023-11** — Lantern filed a Form D after selling $500,000 of a planned $2.5 million debt and warrant offering to nine investors.
- **2023-12** — Lantern completed the NIA Start-Up Challenge and was named one of the program's $60,000 prize winners.

## Links

- Website: https://www.lanternlaboratory.com/
- LinkedIn: https://www.linkedin.com/company/lantern-laboratory-inc
- YouTube: https://www.youtube.com/watch?v=aoq-jdoLncY

---

Profile page: https://yespress.io/lantern-laboratory-inc
Published by YesPress — https://yespress.io
Last updated: 2026-08-20